Electromed exhibits a compelling growth trajectory driven by its specialized sales force, which has successfully propelled revenue to $18.6 million in 2026Q3. The company maintains a fortress balance sheet with zero debt and a current ratio of 4.91, providing ...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 25, 2026 | $0.39+23.1% vs $0.32 | $19M+0.4% vs $19M |
Q2 2026 May 12, 2026 | $0.35+34.6% vs $0.26 | $19M+5.5% vs $18M |
Q1 2026 Feb 10, 2026 | $0.32+18.5% vs $0.27 | $19M+4.7% vs $18M |
Q4 2025 Nov 12, 2025 | $0.25+13.6% vs $0.22 | $17M-7.7% vs $18M |
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Participate in the H.C. Wainwright 28th Annual Global Investment Conference and LD Micro 20th Annual Main Event.
Electromed's direct-to-patient model, broad payer coverage, and disciplined sales execution support durable SmartVest growth. The bronchiectasis market remains substantially underpenetrated, leaving a long runway for greater HFCWO adoption. Hospital revenue is volatile, but the channel remains small and full-year hospital sales still increased.
Electromed, Inc. (ELMD) Q4 2026 Earnings Call Transcript
Electromed, Inc. (ELMD) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.25 per share a year ago.
Benchmark ELMD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Electromed, Inc. (ELMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $27.57 | $228.28M | 32.06 | 16.97% | 11.78% | 17.18% | — | |
| $5.09 | $137.81M | -5.99 | 3.86% | -6.94% | -13.17% | — | |
| $99.97 | $6.51B | 29.32 | 0.5% | 17.69% | 23.27% | — | |
| $2.00 | $84.47M | -1.50 | 8.01% | -55.03% | -96.66% | — | |
| $173.60 | $8.69B | 34.31 | 14.17% | 11.54% | 12.67% | — | |
| $103.53 | $180.32B | 27.83 | 5.67% | 13.91% | 12.09% | — |
Electromed, Inc. (ELMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Electromed, Inc. (ELMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 25, 2026·SEC
May 12, 2026·SEC
Feb 10, 2026·SEC
Get notified when ELMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Electromed, Inc. (ELMD) stock FAQ — growth, dividends, profitability & financials explained
Electromed, Inc. (ELMD) reported $73.8M in revenue for fiscal year 2025. This represents a 743% increase from $8.8M in 2008.
Electromed, Inc. (ELMD) grew revenue by 17.0% over the past year. This is strong growth.
Yes, Electromed, Inc. (ELMD) is profitable, generating $11.3M in net income for fiscal year 2025 (11.8% net margin).
Electromed, Inc. (ELMD) has a return on equity (ROE) of 17.2%. This is reasonable for most industries.
Electromed, Inc. (ELMD) generated $9.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
